Skip to main navigation
Skip to search
Skip to main content
University of St Andrews Research Portal Home
Help & FAQ
Home
Profiles
Research output
Datasets/Software
Research units
Projects
Activities
Impacts
Prizes
Press/Media
Student theses
Search by expertise, name or affiliation
Benefit-risk assessment of long-acting beta(2)-agonists in asthma
C M Jackson, B Lipworth
School of Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Benefit-risk assessment of long-acting beta(2)-agonists in asthma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Airway Smooth Muscle
33%
Anti-Inflammatory Drug
33%
Antiinflammatory Activity
66%
Asthma
100%
Beta 2 Adrenergic Receptor Stimulating Agent
100%
Budesonide/Formoterol
33%
Drug Dose Titration
33%
Fluticasone Propionate
33%
Leukotriene Receptor Blocking Agent
33%
Lung
66%
Salmeterol
33%
Pharmacology, Toxicology and Pharmaceutical Science
Anti-Inflammatory Drug
100%
Asthma
100%
Beta 2 Adrenergic Receptor Stimulating Agent
100%
Budesonide Plus Formoterol
33%
Fluticasone Propionate
33%
Inflammation
33%
Leukotriene Receptor Blocking Agent
33%
Salmeterol
33%